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Investigations about the anxiolytic activity of the cholecystokinin-B-receptor- 
antagonist L365.260 in two animal-models of anxiety in rats  
The identification of the neurobiological mechanisms of anxiety is a precondition for the devel-
opment of pharmacological therapy strategies. The role of the involved neuronal transmission 
systems is of particular interest. The neuropeptide cholecystokinin (CCK) is supposed to play a 
role in the transmission of neuronal impulses in processes of anxiety. At least it could modulate 
other transmitting systems in sense of a positive or negative regulation. The CCKB-receptor 
seems to play a major role in this process. Theoretically, inhibitors of CCK binding at the CCKB-
receptor are capable to suppress transmitter-related anxiety reactions. The aim of experimental 
research with CCKB-receptor-antagonists is the development of clinically potent anxiolytics. 
The benzodiazepin derivate L365.260 is a selective antagonist at the CCKB-receptor. In two ani-
mal-models - a modified open-field as conflict-test and the elevated-plus-maze - the anxiolytic 
potential of L365.260 was evaluated for different dosages and administrations (centrally: into the 
ventricle and the hippocampus; peripherally: intraperitoneal) and under different surrounding 
conditions of different aversive potential (light, noise). Because Wistar-rats show different strain-
dependent anxiety-related behaviours, Winkelmann-Wistar-rats (low trait-anxiety) and BgVV-
Wistar-rats (high trait-anxiety) have been compared. All experiments were carried out using con-
trol-groups of vehicle-treated animals. The results were compared with the efficacy of so-called 
standard anxiolytics in the chosen experimental settings. Additional data were obtained for the 
efficacy of anxiety-inducing CCKB-receptor-agonists and for one agonist of the serotonergic 
transmission system. Control trials have been performed to differentiate central effects from pe-
ripheral effects transmitted by the nervus vagus. A new simple inspectoric control procedure for 
the successful performance of the vagotomy has been established and validated. The plasmatic 
availability and the CNS-penetration have been proofed by plasma- and tissue-concentration 
measures. 
After systemic administration, L365.260 shows a receptor-transmitted and dose-dependent effect, 
which can be neutralised by agonists. After central administration only minor effects can be 
shown. This might be due to the fact, that the inner anxiety status of the animals is changed by 
the central modus of administration. Looking at the inconsistent results obtained with the vago-
tomy trials one has to consider the traumatic stress of the operation to have a non calculable 
influence on the function of transmitter systems. Consistently a differentiation between the ef-
fects transmitted by central receptors and peripheral receptors or vagus receptors are not possible. 
Summary 
131 
These results confirm the role of the CCKB-receptor in the regulation of anxiety related proc-
esses. The inconsistent effects of the tested substances are similar to the results found in the 
literature and do underline on the one hand the distinct sensibility of animal-models for the 
evaluation of anxiety related processes to varying test conditions. On the other hand they show 
that the effects of single test substances can be different in different animal-models. The adoption 
of data obtained in animal-models to the pharmacobiological processes in human anxiety is 
therefore clearly limited. 
The future investigation of potential anxiolytics like L365.260 should be intensified by using 
animal-models, with a more ethological approach in the interpretation and recording of behav-
iour displayed in the tests. For the acute central administration, experimental conditions should 
be developed, which do not influence the inner anxiety status of the animals. An increased recep-
tor affinity of CCKB-receptor-antagonists and a better CNS-permeability might be helpful 
improvements. Effects like tolerance and dependency, which haven't been described yet, have 
definitely to be excluded for clinical use. Therefore the effects of chronic treatment have to be 
further investigated to fasten the development of clinically usable anxiolytics. 
 
